The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Substrate-Dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates
Abstract
Inhibition of cytochrome P450 catalytic activity is a principal mechanism for pharmacokinetic drug-drug interactions. Rapid, in vitro testing for cytochrome P450 inhibition potential is part of the current paradigm for identifying drug candidates likely to give such interactions. We have explored the extent that qualitative and quantitative inhibition parameters are dependent on the cytochrome P450 (CYP) 3A4 probe substrate. Inhibition potential (e.g., IC(50) values from 8-point inhibition curves) or activation potential for most compounds varied dramatically depending on the fluorometric probe substrates for CYP3A4 [benzyloxyresorufin (BzRes), 7-benzyloxy-4-trifluoromethylcoumarin (BFC), 7-benzyloxyquinoline (BQ), and dibenzylfluorescein (DBF)]. For 21 compounds that were primarily inhibitors, the range of IC(50) values for the four substrates varied from 2.1- to 195-fold with an average of 29-fold. While the rank order of sensitivity among the fluorometric substrates varied among the individual inhibitors, on average, BFC dealkylation was the most sensitive to inhibition, while BQ dealkylation was least sensitive. Partial inhibition was observed with BzRes and BQ but not for BFC and DBF. BzRes was more prone to activation, whereas dramatic changes in IC(50) values were observed when the BQ concentration was below the S(50). Three different correlation analyses indicated that IC(50) values with BFC, BQ, and DBF correlated well with each other, whereas the response with BzRes correlated more weakly with the other substrates. One of these correlation analyses was extended to the percent inhibition of 10 microM inhibitor with the standard CYP3A4 probe substrates testosterone, midazolam, and nifedipine. In this analysis the responses with BQ, BFC and DBF correlated well with testosterone and midazolam but more poorly with nifedipine. In the aggregate, BFC and DBF appear more suitable as an initial screen for CYP3A4 inhibition. However, the substrate-dependent effects reported here and by others indicate that all CYP3A4 inhibition data should be interpreted with caution.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yung-Chi, C., & Prusoff, W. H. (1973) · Biochemical Pharmacology · doi:10.1016/0006-2952(73)90196-2 · Cited by 12,922
Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., & Guengerich, F. P. (1994) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22379-5 · Cited by 2,785 · cited 1×
“In contrast, 1 mg/ml liver microsomal protein contains on average 100 nM CYP3A4 (Shimada et al., 1994) in addition to other enzymes that may contribute to inhibitor depletion.”
Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4.
Kronbach, T., Mathys, D., Umeno, M., Gonzalez, F. J., & Meyer, U. A. (1989) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09118-7 · Cited by 532
Korzekwa, K. R., Krishnamachary, N., Shou, M., Ogai, A., Parise, R. A., Rettie, A. E., Gonzalez, F. J., & Tracy, T. S. (1998) · Biochemistry · doi:10.1021/bi9715627 · Cited by 511
Microtiter Plate Assays for Inhibition of Human, Drug-Metabolizing Cytochromes P450
Crespi, C. L., Miller, V. P., & Penman, B. W. (1997) · Analytical Biochemistry · doi:10.1006/abio.1997.2145 · Cited by 406
Self-citationCooperativity in Oxidations Catalyzed by Cytochrome P450 3A4
Ueng, Y.-F., Kuwabara, T., Chun, Y.-J., & Guengerich, F. P. (1997) · Biochemistry · doi:10.1021/bi962359z · Cited by 383
CYP3A4 drug interactions: correlation of 10 in vitro probe substrates
Kenworthy, Bloomer, Clarke, & Houston (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00073.x · Cited by 336
Role of Cytochrome P450 Enzymes in Drug-Drug Interactions
Guengerich, F. P. (1997) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)60200-8 · Cited by 284
Human Cytochrome P-450 3A4: In Vitro Drug-Drug Interaction Patterns Are Substrate-Dependent
Wang, R. W., Newton, D. J., Liu, N., Atkins, W. M., & Lu, A. Y. H. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15374-3 · Cited by 240
Cited by
Predicting in vivo drug interactions from in vitro drug discovery data
Wienkers, L. C., & Heath, T. G. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1851 · Cited by 904
Mechanism-Based Inhibition of Cytochrome P450 3A4 by Therapeutic Drugs
Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M., & McLeod, H. L. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544030-00005 · Cited by 517
Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7
Williams, J. A., Ring, B. J., Cantrell, V. E., Jones, D. R., Eckstein, J., Ruterbories, K., Hamman, M. A., Hall, S. D., & Wrighton, S. A. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.8.883 · Cited by 471
Profiling drug-like properties in discovery research
Di, L., & Kerns, E. H. (2003) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(03)00055-3 · Cited by 278
Atypical Kinetic Profiles in Drug Metabolism Reactions
Hutzler, J. M., & Tracy, T. S. (2002) · Drug Metabolism and Disposition · doi:10.1124/dmd.30.4.355 · Cited by 261
Metadata
- Authors
- Stresser, D. M., Blanchard, A. P., Turner, S. D., Erve, J. C. L., Dandeneau, A. A., Miller, V. P., & Crespi, C. L.
- Venue
- Drug Metabolism and Disposition
- Publisher
- Elsevier BV
- Published
- 2000-12
- Volume
- 28
- Issue
- 12
- Pages
- 1440-1448
- ISSN
- 0090-9556 (ISSN-L)
- OpenAlex
- W2142366726
- Cited by
- 273
- References
- 18
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Substrate-Dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates. https://app.cochat.ai/papers/10.1016/s0090-9556(24)13672-0
- The paper
- Stresser, D. M., Blanchard, A. P., Turner, S. D., Erve, J. C. L., Dandeneau, A. A., Miller, V. P., & Crespi, C. L. (2000). Substrate-Dependent Modulation of CYP3A4 Catalytic Activity: Analysis of 27 Test Compounds with Four Fluorometric Substrates. Drug Metabolism and Disposition. https://doi.org/10.1016/s0090-9556(24)13672-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.